2nd-line Tarceva+ALIMTA for EGFR mutation negative non-small, non-squamous lung cancer (TALIMTA STUDY)
Not Applicable
- Conditions
- non-sq NSCLC
- Registration Number
- JPRN-UMIN000002453
- Lead Sponsor
- Respiratory Medicine, Kyoto University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1)previous chemotherapy with erlotinib, gefitinib, or pemetrexed 2)interstitial pneumoia/active lung fibrosis on chest x-ray 3)massive or uncontrolable pleural effusion 4)symptomatic brain metastasis 5)active concomitant malignancy 6)severe comorbidity 7)pregnant or lactating woman 8)history of severe drug allergy 9)psychiatry disease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method disease control rate
- Secondary Outcome Measures
Name Time Method overall survival, progression-free survival, 1-year survival, safety